REGULATORY
MHLW Panel Recommends 3 Products Including Talion for Approval as “Behind-the-Counter Drugs”
A health ministry committee on nonprescription Drugs recommended approval for three anti-allergy drug products as “behind-the-counter (BTC) drugs” at a meeting on December 9. The three products are Mitsubishi Tanabe Pharma’s Talion (bepotastine), Bayer Yakuhin’s Claritin (loratadine; ordinary tablets and…
To read the full story
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Health Minister Signals Early March Approval for iPSC Products
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





